NCT00406120

Brief Summary

Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started May 2007

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 29, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 4, 2006

Completed
5 months until next milestone

Study Start

First participant enrolled

May 1, 2007

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

June 26, 2018

Status Verified

June 1, 2018

Enrollment Period

3 years

First QC Date

November 29, 2006

Last Update Submit

June 21, 2018

Conditions

Keywords

eyeuveairischoroidciliary bodymelanomairis melanomachoroidal melanomaciliary body melanomauveal melanomaposterior uveal melanomaprognosismetastasisgenetic testingmolecular testinggene expression profiling

Outcome Measures

Primary Outcomes (1)

  • Presentation of Primary Tumor to Metastasis

    60 months

Interventions

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients have uveal melanoma and are being treated wither by enucleation or plaque radiotherapy.

You may qualify if:

  • clinical diagnosis of melanoma of the iris, ciliary body and/or choroid
  • treatment to include enucleation, radiotherapy or local tumor resection

You may not qualify if:

  • evidence of marked tumor necrosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Publications (5)

  • Onken MD, Worley LA, Davila RM, Char DH, Harbour JW. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn. 2006 Nov;8(5):567-73. doi: 10.2353/jmoldx.2006.060077.

    PMID: 17065425BACKGROUND
  • Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006 May 1;66(9):4602-9. doi: 10.1158/0008-5472.CAN-05-4196.

    PMID: 16651410BACKGROUND
  • Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol. 2005 Oct;140(4):748-9. doi: 10.1016/j.ajo.2005.04.024.

    PMID: 16226537BACKGROUND
  • Faulkner-Jones BE, Foster WJ, Harbour JW, Smith ME, Davila RM. Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol. 2005 May-Jun;49(3):297-308. doi: 10.1159/000326153.

    PMID: 15966293BACKGROUND
  • Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004 Oct 15;64(20):7205-9. doi: 10.1158/0008-5472.CAN-04-1750.

    PMID: 15492234BACKGROUND

MeSH Terms

Conditions

Uveal NeoplasmsChoroid NeoplasmsIris NeoplasmsMelanomaUveal MelanomaNeoplasm Metastasis

Interventions

Biopsy, Fine-Needle

Condition Hierarchy (Ancestors)

Eye NeoplasmsNeoplasms by SiteNeoplasmsEye DiseasesUveal DiseasesChoroid DiseasesIris DiseasesNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsSkin DiseasesSkin and Connective Tissue DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Biopsy, NeedleBiopsyCytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativePuncturesInvestigative Techniques

Study Officials

  • J. William Harbour, MD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 29, 2006

First Posted

December 4, 2006

Study Start

May 1, 2007

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

June 26, 2018

Record last verified: 2018-06

Locations